MegaStream TechBio Emerges as AI-Powered Biologics Factory with Landmark Filing

In this era, the old is crumbling while the new is emerging.

WhenSpaceXSurged on the First Day of Listing2With a market capitalization in the trillions of dollars, Musk has launched not only a space opera exploring the vast cosmos but also ignited an earth-shatteringAICloud. The familiar old world crumbled, silicon-based andAIThe sci-fi aesthetic being crafted is becoming a fresh reality.

The singularity of innovative drugs has also arrived, with previous R&D models constrained by“Inverse Moore's Law”, approximately every9years, the R&D costs will double, and all of this will beAIDisruption.

6Month15Day, Shanghai, aAIThe Pharmaceutical Super Factory Is Born.

Harbour BioMed and BioMap Join Forces to Co-establish a NewAIPipeline R&D CompanyMegaStream TechBio, this is a historic moment as the global drug development leadership platform meets the most powerful foundational large model for life sciences, markingAIPharmaceuticals is transitioning from technological incubation to industrial-scale implementation.

MegaStreamThe mission of a Gigafactory is to achieve mass production.FIC/BICComplex Macromolecule Pipeline, with the operational process as follows:First, establish a world-class exclusiveAIDD Infrastructure Platform,Harbour BioMed offers globally uniqueHarbour Mice^®The vast amount of high-quality data accumulated by the fully human antibody platform, combined with BioMap’s globally leading foundational large model for life sciencesxTrimo V4(Benchmarking NVIDIABioNeMo, GoogleDeepMind AlphaFold), forming a system with self-evolving capabilitiesMegaStreamPersonalized Exclusive Large Model;Then, withMegaStreamEstablish a new generation of intelligent high-throughput dry-wet closed-loop laboratories based on large models,ProjectedAI Enhanced Efficiency of Native Molecular Validation500%The above, data accumulation efficiency increased by more than10times;The result is the scaled-up production of a new generation of high-quality pipeline molecules,Finally completed the clinical trial by Harbour BioMed+Operations.

MegaStreamFunctioning as a pipeline factory, forming aAIA complete value chain loop from R&D to clinical implementation, with a monetization model ofBDor sell the pipeline, with both parties sharing potential upfront payments, success milestones, and royalty distributions in accordance with industry practice.

MegaStreamwill be implemented and operationalized at the fastest pace, running through from a practical combat stanceAIAn Innovative Closed-Loop from Design to Clinical Validation.

01 
Unprecedented Implementation Intensity

Action, immediate action.

We in the "AIPharmaceutical Hidden Champion: Why Harbour BioMed?》 points out, “2026, will beAI“The Year of Large-Scale Commercialization in the Pharmaceutical Industry.”

Footsteps of landing are everywhere.

6Month11On [date], Takeda Pharmaceutical announced the new generation of oralTYK2InhibitorZasocitinibIn the treatment of moderate-to-severe plaque psoriasisIIIhead-to-head defeat in phase studiesBMSDrugs Targeting the Same AntigenSotyktu. Notably,Zasocitinibis Takeda Pharmaceutical's40an upfront payment of hundreds of millions of US dollars for the acquisition ofAIThe success of this head-to-head trial of the small-molecule inhibitor designed by the pharmaceutical company also marksAIA Victory in the Manual Synthesis of Molecules by Humans.

6Month10On [date], ByteDanceAIPharmaceutical Spin-off Officially Launches Separation and Independent Fundraising Process, Signifying That ByteDance Is Pushing a Long-Term Internally Incubated Cutting-Edge Technology Business Line to the External Market, Entering the Industrialization Phase, Also MeaningAIThe pharmaceutical industry enters an arms race phase.

AIThe window of opportunity for the pharmaceutical industry has opened; the wheel of time waits for no one. The scale and depth of the collaboration between Harbour BioMed and BioMap are unprecedented.

1. Joint venture entity binding.Breaking TraditionAILoose, Single-Project Collaboration Paradigm Between Enterprises and Innovative Pharmaceutical Companies: Establishment of Independent R&D Joint VenturesMegaStream TechBio, and Harbour BioMed will serve as the lead initiator, forMegaStreamBy opening up its globally unique fully human antibody platform, extensive target biology expertise, and global clinical development advantages, BioMap will serve as a co-initiator, providing the underlyingAI Technology enablement, model engineering support, and intelligent R&D capabilities. The two parties also made comprehensive arrangements for the distribution of benefits derived from pipeline outputs.

Second, long-cycle, full-chain translation.Upgrading from fragmented early-stage molecular design collaborations to hundreds ofFIC/BIC Scaled R&D of the pipeline, leveraging Harbour BioMed’s clinical development and operational capabilities to bridge the gap fromAIGenerate a complete chain leading to clinical value, implementing an industrial closed loop from early-stage research to commercial monetization.

Time Waits for No One: Harbour BioMedAIPharmaceuticals: Multi-line Layout and Repeated Investment Increases.

Harbour BioMed's FirstAICandidate Drug This Year5Yuedu delivers outstanding preclinical data, leveragingHu-mAtrIx™Next-Generation Targets Developed by the AI PlatformACVR2A/2BMonoclonal Antibody DrugsLET003, exhibiting superior pharmacokinetic profiles compared to multiple competitor molecules. When used in combination with semaglutide,LET003Significantly enhances fat loss effects and effectively preserves lean body mass. At lower doses,LET003can achieve efficacy comparable to that of higher dosesbimagrumabSignificant promotion of lean body mass increase, demonstrating its potential in the treatment of obesityBICPotential.

Jointly FoundedMegaStream, and Harbour BioMedAIPart of the larger puzzle, involvingHarbour Mice^®Proprietary high-quality antibody data, which remains a core asset of Harbour BioMed, is licensed by Harbour BioMed toMegaStreamUse.

02 
World-classAIDD Infrastructure Platform

AITechnologically Reversible“Inverse Moore's Law”。

According to Deloitte’s “Evaluation of Returns on Pharmaceutical Innovation,” the overall return on R&D investment in the biopharmaceutical sector has, since2010annual10.1%Continuously declining,2024Annual maintenance approximately4.1%level.

AIIt is being upgraded from a standalone tool into the underlying infrastructure of the R&D and production system. According to NVIDIA's public information,AIThe technology demonstrates significant advantages across all stages of drug development. In the early discovery phase, the time required can be reduced to one-third of the original duration, and costs can be lowered to 1/200th, resulting in an overall reduction of nearly40%; According toTechEmergenceData,AITechnology can increase the success rate of new drug development in the clinical phase from12%Increase to approximately14%。

AIThe Chinese Solution for Pharmaceutical Manufacturing Is Here.

Harbour BioMed holds the world's largest fully human heavy-chain antibody database.Data resources areAIThe core production factors in the upstream of the pharmaceutical industry chain, whose quality and abundance directly determine the prediction accuracy and generalization ability of the model. Harbour BioMed possesses globally leadingHarbour Mice^®Fully human antibody technology platform and the vast amount of high-quality antibody data accumulated over more than ten years, which particularly includes functional, druggability, safety, and clinical data from the mid-to-late stages of antibody discovery. These proprietary data assets constitute the trainingAIThe model’s foundational data supports end-to-end algorithm development, spanning from target discovery to clinical prediction.

BioMap is a global leader in foundational large models for life sciences.its independently developed2680billion-parameterxTrimo V4Large models achieve greater accuracy by decoding the underlying principles of genes, proteins, cells, and biological systems.AIPredictive capability, has been in20in more than [X] subfields of life sciences300among the remaining prediction tasks, achieving industry-leading (SOTA) performance, and won the championship of the first World Virtual Cell Challenge.

Proprietary High-Quality Antibody Data+Foundation Large Model for Life Sciences, CatalyzingMegaStreamPersonalized, Proprietary Large Model: Systematic, Targeted Training, Optimization, and Iteration Tailored to the Distinct Characteristics of Complex Macromolecular Drugs Versus Conventional Generic Protein and Antibody Therapeutics.

Two Powerhouses Join Forces to Create a World-ClassAIDriving Complex Macromolecular DrugsAIDD Infrastructure Platform,Geared towards next-generation multispecific antibodies,XDCConjugated Drugs, In VivoCAR-T. Inhalation/Deep optimization of complex macromolecules, such as oral biologics, delivers robust performance advantages and enables an end-to-end workflow from sequence generation to developability optimization.AIDesign capability.

03 
Scaled Production of Pipeline Factory

OnceAIDDInfrastructure Platform/Successfully developed a dedicated large model, forming“Data-Model”The Positive Feedback Effect: The Rise of Next-Generation Superfactories for Complex Macromolecules Will Be Unstoppable.

According to Huachuang Securities, leading overseas companies are beginning to shift toward automated wet-lab experimentation to build data flywheels, for exampleRecursionSelf-built intelligent laboratory, operating approximately per week220Passed in 10,000 experiments“AIDesign-Robot Execution-Real-time Feedback”a closed-loop system that autonomously generates high-quality proprietary data in a standardized, high-throughput manner, transforming from a data consumer to a data producer and gradually reducing reliance on public datasets.

Harbour BioMed and BioMap willMegaStreamBuilt on a dedicated large language model, we are co-developing a new generation of intelligent high-throughput dry-wet closed-loop laboratory, with efficiency expected to improve compared to the previous generation of dry-wet closed-loop laboratories.500%The above will significantly accelerate the discovery and iteration pace of complex macromolecular drugs, driving a fundamental transformation in the R&D paradigm andAI provides robust support for the continuous optimization of model capabilities. Meanwhile,AIThe Native Intelligence Lab will increase data accumulation efficiency by more than10times,Expected to generate over the next five years5PBHigh-qualityAI-ReadyLife Science Data, DrivingAIModels Evolve Rapidly.

Thus,AIThe R&D engine is established, and a new generation of pipeline portfolios will surge forth.

The First of Both PartiesAI+Biotechnology-DrivenFICPipeline R&D collaboration commenced in2021years, and subsequently10participated in pipeline attribute prediction, optimization, and generative design during the R&D process of multiple pipelines. In the future, leveraging the newly built next-generationAIComplex Macromolecule Drug R&D Platform, Focusing on Major Unmet Clinical Needs in Cardiovascular, Renal, Anti-Aging, and Oncology Fields,FIC/BICThe R&D capabilities of the pipeline will be significantly enhanced, benefiting Harbour BioMed andMegaStreamProvides robust support for advancing hundreds of innovative pipeline projects in parallel.MegaStreamApprovedAIBy combining model predictions with a small amount of high-precision validation to replace traditional repetitive screening experiments, and leveraging the generative predictive advantages of large models, this approach yields high-quality pipeline molecules with superior performance metrics, more comprehensive property optimization, and more precise programmable controllability.

MegaStreamComplete company establishment and the implementation of the first batch of pipelines in the shortest time possible. Its core management team will be jointly formed by senior executives from multinational pharmaceutical companies and top experts in the field of artificial intelligence, with relevant personnel gradually taking their positions; the initial pipeline consists of the two parties' previous collaborativeAI Drug Development Projects and Newly InitiatedAIcomposed of native pipeline R&D projects, will accelerate the process of clinical translation.

Conclusion

In the face of monumental changes in our era, all anxieties essentially stem from maladaptation. Nassim Nicholas Taleb, author of The Black Swan·Taleb this year2posted a tweet with just one sentence:“20All professions invented in the century are inescapableAIimpact.”

Diligent all day long, advancing with the times.

Harbour BioMed possesses a keen sense of industry trends and forward-looking vision, with the innate capacity for self-evolution and platform advancement ingrained in its DNA.

Exclusive Big Data×Exclusive Large Language Model×A robust pipeline of innovative assets,MegaStreamForAIBorn from the integration of strong resources, with the potential to become a global leader in complex macromoleculesAIBenchmark Enterprise in Drug Development.